Articles tagged with Mouse Models
Scientists have established a mouse model for human malignant mesothelioma, an aggressive cancer originating from the mesothelial lining of the pleural cavity. The model closely resembles human MM, allowing researchers to study disease onset, progression, and test new therapeutic strategies.
Researchers have created a highly accurate mouse model of inflammatory bowel disease (IBD), which closely resembles the most serious form of human ulcerative colitis. Treating the mice with broad-spectrum antibiotics reduced gut inflammation and increased survival, providing hope for new treatments.
Researchers found an association between leptin resistance and high blood pressure in people with Bardet-Biedl syndrome, a rare genetic disorder. Leptin resistance disrupts brain signals that regulate appetite and metabolism.
A study found that neutralizing IL-22 prevents psoriasis-like disease in mice by reducing skin thickening and inflammatory responses. Administering IL-22 into normal mice induced psoriasis-like skin lesions, supporting the role of IL-22 in the disease.
Researchers found that delivering the IL-22 gene to the intestines of mice with ulcerative colitis reduced inflammation and enhanced mucus production. Local delivery of the IL-22 gene also neutralized chemical-induced intestinal inflammation in normal mice, suggesting a potential therapeutic approach for UC.
Researchers at Massachusetts General Hospital have identified a compound, C2-8, that may delay the loss of motor control and reduce neurological damage in a mouse model of Huntington's Disease. The study found that C2-8 slows the progress of HD and shows promise as a potential treatment.
Researchers created a genetically engineered mouse that models both anatomical and behavioral defects of schizophrenia, a complex brain disorder. The new mouse is based on a genetic change in the DISC1 gene, which affects nerve cell function, and shows characteristic defects in brain structure and behavior.
Researchers have developed a groundbreaking new mouse model for lung transplantation, which could lead to breakthroughs in preventing transplant rejection. The study aims to understand the molecular mechanisms controlling lung graft survival and develop therapies to counteract chronic rejection.
Researchers have identified a gene, GLIS2, that protects against a serious kidney disease called nephronopthisis. Mutations in this gene cause the disease, which leads to kidney degeneration and failure.
Scientists have developed a mouse model for synovial sarcoma, revealing that the tumor arises from skeletal muscle precursor cells called myoblasts. The study also showed that expression of a chimeric fusion protein called SYT-SSX in these cells is sufficient to induce synovial sarcoma with 100% penetrance.
New research in mice suggests that reversing CaMKII inhibition alleviates Angelman syndrome neurological problems. The study identifies potential therapeutic targets for treating symptoms, and the findings may apply to other unexplained mental retardation syndromes.
Researchers found that losartan improves muscle regeneration and repair in a mouse model of Duchenne muscular dystrophy, a devastating disease characterized by rapid progression of muscle degeneration. The study also showed that losartan can attenuate the entire disease when treated over time.
U of MN researchers developed a mouse model for centronuclear myopathy, a poorly understood muscle disease. They found that knocking out the gamma actin gene impaired muscle cell function, leading to muscle cell death, and identified this protein as a key player in muscle structure.
Researchers identified a connection between pregnane X receptor (PXR) and neuroprotection in a mouse model of Niemann-Pick type C disease. Activating PXR with known activators, such as dilantin and St. John's Wort, may help clear toxic cholesterol byproducts.
Researchers have discovered that neurons can produce a key protein linked to Alzheimer's disease under certain conditions. The study uses a unique mouse model to show that apoE production is regulated by the brain's response to injury, shedding light on the mechanisms underlying this complex disorder.
Researchers have identified NRL as the earliest marker of rod precursors, allowing them to pinpoint the exact time at which rods are formed. This discovery provides a new vantage point for understanding healthy visual system development and raises the possibility of re-directing cell production to stave off eye disease.
Researchers at Howard Hughes Medical Institute have created a mouse model of medulloblastoma, a common childhood brain cancer. The study found that mice lacking the XRCC4 gene or both XRCC4 and p53 died early from tumors, which displayed genetic abnormalities characteristic of human medulloblastomas. This new model will help understand...
Researchers discovered a mechanism by which misfolded SOD1 proteins form aggregates that kill motor neurons in ALS. The normal form of SOD1 is recruited to participate in disease formation through intermolecular disulfide bonds, providing potential sites for therapeutic intervention.
Karen Duff, a young British scientist, received the Potamkin Prize for her innovative work on developing transgenic mouse models of age-related human brain diseases. Her research has led to significant advancements in understanding Alzheimer's disease and identifying potential treatments.
Researchers have discovered that Alzheimer's disease is caused by abnormal cell division in neurons, which starts months before amyloid plaques form. The study suggests that another cellular problem triggers the disease process after abnormal cell cycling begins.
Researchers at UCSD develop mice models expressing high amounts of alpha-synuclein to study its effects on the nervous system. The models aid in understanding the causes of multiple system atrophy and developing treatments to slow disease progression, potentially benefiting patients with Parkinson's disease as well.
Researchers at EMBL and universities in Heidelberg and Ulm found that blocking a specific signal within brain cells may help prevent cell death after a stroke. The study suggests new therapies could be developed by controlling a molecule involved in passing the signal.
A new therapeutic target has been identified in the inherited brain tumor disorder neurofibromatosis 1 (NF1). Fumagillin, an established drug, has been found to suppress the activity of MetAP2, which is abnormally high in NF1-associated brain tumors. This discovery may lead to new treatments for patients with NF1.
A mouse model of Rett Syndrome displays reduced cortical activity, suggesting a primary cellular defect. The study found that the excitatory-inhibitory balance in the cortex is shifted towards inhibition, which may underlie cognitive, motor, and social symptoms in RTT.
Researchers at U Iowa have made significant breakthroughs in treating Huntington's disease by reducing protein levels in genetically engineered mice. The study, published in PNAS, demonstrates the effectiveness of RNA interference in improving HD-like symptoms in a mouse model.
A new mouse model mimics the effects of low-dose aspirin therapy, reducing platelet aggregation and inhibiting thrombosis. The study suggests that low-dose aspirin treatment may prevent preeclampsia without compromising reproductive function.
The study developed mice with a mutant form of ELOVL4, which causes significant lipofuscin accumulation and photoreceptor death, closely resembling human AMD and STGD. This model now permits testing of potential therapies for the dry version of age-related AMD and STGD.
Researchers found that a protein called STAT3 is crucial for the development of psoriasis and can be reversed with a specific treatment. The study's findings offer a potential new target for medications to relieve symptoms of psoriasis.
The study found that LR11 plays a crucial role in regulating beta amyloid levels, suggesting its potential as a therapeutic target for Alzheimer's disease. The Emory researchers used lentiviruses to selectively reduce and enhance LR11 expression in mouse brains and cultured cells.
Dr. Li-Huei Tsai's groundbreaking study reveals p25 protein's role in Alzheimer's disease, a key feature of which is the presence of beta amyloid plaques and neurofibrillary tangles. The research also suggests an intervention after stroke could lower or prevent additional risk of Alzheimer's
Asthma researchers at Yale discovered a new protein, AMCase, that contributes to inflammation in the airways. Blocking this protein may provide relief for humans with asthma, but its mechanism of action is not yet fully understood.
A research study found that inhibition of cathepsin cysteine proteases impairs tumor growth and progression in transgenic mouse models of cancer. Treatment with a pharmacological inhibitor also disrupted both early and late stages of tumor development, suggesting its potential as an anticancer therapeutic.
Researchers have created a new mouse model of Alzheimer's disease to study the effects of toxic protein p25 on brain degeneration. The model, developed by Harvard Medical School scientists, shows high levels of p25 accumulation leading to neuronal death and tau pathology after just 12 weeks.
The article describes a biologically well-characterized mouse model for cystinuria type I, a human disease caused by impaired renal function. The model closely mimics the human disease state and is expected to improve biomedical research in areas like disease analysis and drug testing.
Researchers have developed a new mouse model that mimics progeria, a rare condition characterized by accelerated aging. The mouse model shares symptoms with human patients, including growth retardation, skin thinning, and premature death, providing valuable tools for studying the aging process.
Researchers have discovered that mouse models of Alzheimer's disease duplicate their DNA and make an attempt at cell division, just like human nerve cells. This suggests that the underlying mechanism of cell death is the same in both species, potentially making these model systems more suitable for testing experimental therapies.
Researchers created a mouse model of Rett syndrome to study the gene MECP2 and its role in fine-tuning the developing nervous system. The study may improve understanding of the disorder and lead to potential treatments for patients.